Product Information
ASPIRIN-DIPYRIDAM ER 25-200 MG is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $0.5586 per EA under NDC 68462040560. Its NADAC has been published 339 times since Apr 8, 2020.
FDA first approved this application on May 24, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25; 200 mg/1; mg/1
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462040560
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ASPIRIN; DIPYRIDAMOLEApproval Type
Generic (ANDA)
FDA Application
ANDA210318FDA Approved
5/24/2019
TE Code
AB
On Market Since
5/24/2019
Pharmacological Classes
Price Statistics
The NADAC for ASPIRIN-DIPYRIDAM ER 25-200 MG has been published 339 times since Apr 8, 2020, and over the history we have for it it has declined 76.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5586 per EA |
|---|---|
| All-time high | $2.3958 (Apr 15, 2020) |
| All-time low | $0.5561 (Mar 18, 2026) |
| 52-week high | $0.6072 |
| 52-week low | $0.5561 |
| Median price | $0.7574 |
| Average price | $0.8694 |
| Largest weekly change | +44.2% (Apr 21, 2021) |
| Weeks tracked | 339 |
| Tracking since | Apr 8, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ASPRIN AND EXTENDED-RELEASE DIPYRIDAMOLE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ASPRIN AND EXTENDED-RELEASE DIPYRIDAMOLE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ASPIRIN-DIPYRIDAM ER 25-200 MG?
The current National Average Drug Acquisition Cost (NADAC) for ASPIRIN-DIPYRIDAM ER 25-200 MG, manufactured by Glenmark Pharmaceuticals Inc., USA, is $0.5586 per EA (NDC 68462040560), effective Sep 30, 2026.
How has the price of ASPIRIN-DIPYRIDAM ER 25-200 MG changed over time?
Over the history we have for it, the NADAC for ASPIRIN-DIPYRIDAM ER 25-200 MG has declined 76.7%. It has been tracked across 339 weekly CMS publications since Apr 8, 2020.
What are the highest and lowest recorded NADAC prices for ASPIRIN-DIPYRIDAM ER 25-200 MG?
Since Apr 8, 2020, the NADAC for ASPIRIN-DIPYRIDAM ER 25-200 MG has ranged from a low of $0.5561 (Mar 18, 2026) to a high of $2.3958 (Apr 15, 2020), with a median of $0.7574 per EA.
Are there cheaper alternatives to ASPIRIN-DIPYRIDAM ER 25-200 MG?
No other NADAC-published product currently shares the active ingredient and strength of ASPIRIN-DIPYRIDAM ER 25-200 MG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ASPIRIN-DIPYRIDAM ER 25-200 MG?
ASPIRIN-DIPYRIDAM ER 25-200 MG (NDC 68462040560) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.